BTK 抑制剂:过去,现在和未来
Allison Cool1, Tiffany Nong1, Skye Montoya1
1Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, Miami, FL, USA.
Trends in pharmacological sciences
|July 18, 2024
概括
新的布鲁顿是新的布鲁顿.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 布鲁顿的氨酸激酶 (BTK) 抑制剂改变了B细胞淋巴瘤的治疗方法,特别是在慢性淋巴细胞白血病 (CLL) 中.
- 易布鲁替尼是第一类BTK抑制剂,为此铺平了道路,但新的共价抑制剂提供了更好的安全性,同时仍然与耐药性突变作斗争.
- 像皮尔托布鲁丁尼布这样的非共价BTK抑制剂的出现标志着一个新的阶段,为复发性/耐药性CLL提供了替代方案,并促使对预先治疗的评估.
研究的目的:
- 审查布鲁顿氨酸激酶 (BTK) 抑制剂开发的最新进展.
- 探索BTK抑制剂的不断变化的环境,包括共价和非共价剂,以及它们的潜在应用.
- 讨论BTK抑制剂和BTK降解剂在治疗B细胞恶性瘤和自身免疫性疾病中的未来发展轨迹.
主要方法:
- 关于BTK抑制剂的最近临床试验和临床前研究的文献综述.
- 分析与共价BTK抑制剂相关的耐药性机制.
- 评估新兴的非共价BTK抑制剂和BTK降解剂的疗效和安全性.
主要成果:
- 性BTK抑制剂已经显示出更好的安全性,但面临的耐药性挑战.
- 非共价BTK抑制剂,如皮尔托布鲁替尼,正在获得引力,最近批准了复发性/耐火性CLL.
- 新的BTK抑制剂和BTK降解剂正在研究B细胞癌和自身免疫性疾病中的更广泛应用.
结论:
- BTK 抑制剂领域正在迅速发展,非共价抑制剂将扮演重要角色.
- 单独或组合使用非共价BTK抑制剂在前期治疗中的最佳使用需要进一步确定.
- BTK 抑制剂和降解剂代表了各种B细胞相关疾病和自身免疫性疾病的有希望的治疗途径.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
155
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
155
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Transducer Mechanism: Enzyme-Linked Receptors
2.4K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.4K
Tumor Immunotherapy
504
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
504


